1Melief CJ. Cancer immunotherapy by dendritic cells [J] . Immunity, 2008, 29 (3) : 372-383.
2Park HY, Jin Jo, Song MG, et al. Expression of dendritic cell markers on cultured neut rophils and its modulation by ant iapopt ot ic and pro - apoptotic corn pounds [J]. Exp Mol Med, 2007, 31 (4): 439- 449.
3Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic-cells [J] . Annu Rev Immunol, 2000, 18: 761 - 811.
4Wu L, Liu YJ. Development of Dendritic-Cell Lineages [J] . Immunity, 2007, 26 (6): 741-750.
5Nagaraj S, Ziske C, Sehmidt Wolf IG. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral in ter- leukin-2 gene transfer [J] . Genet Vaccines Ther, 2004, 2 (1): 12.
6T ohansson U, Wahher- Jallow L, Smed- S orensen A, et al. Triggering of dendritic cell responses after exposure t o act ivat ed, but not rest ing, apopt ot ic PBMCs [J].Immunol, 2007, 1179 (3): 1711- 1720.
7Or Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I /H trial using an autologous melano- ma cell/dendritic cell vaccine [J]. Can cer Immunol Immunother, 2003, 52 (6): 387-395.
8Bennaeeur K, Chapman JA, Touraine JL, et al. Immunosuppressive networks in the tumour environment and their effect in dendritic cells [J] . BiochimBiophysActa, 2009, 1795 (1): 16-24.
9Gabrilovich D. Mechanisms and functional significance of tumor induced dendritic cell defects [J] . Nat Rev Immunol, 2004, 4: 941- 952.
10Meht a BA, Schmid-t Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokineinduced CD3-4-CD56-4-killer cells [J]. Blood, 1995, 86 (9): 3493-3499.
